Axsome Therapeutics: All Eyes On Auvelity Launch
Shares of Axsome Therapeutics have posted a 30% gain so far in 2022. Read more to understand why this stock needs to be watched.
Source: seekingalpha.com
📰 Compass Pathways News
Page 22 - Compass Pathways News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Compass Pathways. Real-time updates on events, politics, business and more.
PTSD: Clinical trial examines 'magic' mushrooms as treatment
A Nova Scotia-based company has received Health Canada approval to conduct a clinical trial to determine if psilocybin, a psychedelic compound found in magic mushrooms, can help those with PTSD who are treatment-resistant.
Don Hunter Johns Hopkins University Halucenex Life Sciences Inc National Institute Of Health Centre For Addiction Health Canadafor
Source: ctvnews.ca
Main Sequence Ventures, Lionheart Ventures back Aussie psychedelics start-up Psylo
Main Sequence Ventures-backed Psylo is developing new therapies to treat mental illness modelled on naturally occurring psychedelics such as psilocybin.
Gabrielle Munzer Multidisciplinary Association For Psychedelic Drug Administration Australian Financial Review Multidisciplinary Association Psychedelic Studies
Source: afr.com
Compass Pathways: De-Risked (Still Risky) Psychedelics Play Enters Phase 3 (NASDAQ:CMPS)
Compass shares lost 82% of their value over the past 12 months. Read what this may mean for a company bringing a form of therapy using psychedelic drug psilocybin to market. Read more here.
Source: seekingalpha.com
With Promise of Legalization, Psychedelic Companies Joust Over Future Profits
Cash rich start-ups are filing scores of patent claims on hallucinogens like magic mushrooms. Researchers and patient advocates worry high prices will make the therapies unaffordable.
Source: nytimes.com
FY2022 EPS Estimates for COMPASS Pathways plc (NASDAQ:CMPS) Reduced by Analyst
COMPASS Pathways plc (NASDAQ:CMPS – Get Rating) – Investment analysts at Oppenheimer dropped their FY2022 earnings per share estimates for shares of COMPASS Pathways in a research report issued to clients and investors on Wednesday, October 12th. Oppenheimer analyst F. Brisebois now anticipates that the company will post earnings per share of ($2.25) for the […]
United States United Kingdom Banque Cantonale Vaudoise Exchange Traded Concepts Quadrant Capital Group Cantor Fitzgerald
Source: etfdailynews.com
Some new venture firms are so niche that, at first glance, it's easy to laugh off their focus
One way to compete with big generalist funds is to create exactly the opposite thing.
Source: techcrunch.com
COMPASS Pathways Announces Phase 3 Pivotal Program Design
First ever phase 3 program of psilocybin therapy globally scheduled to begin in 2022...
Source: globenewswire.com
Mental Illness Is Not in Your Head - Boston Review
Decades of biological research haven't improved diagnosis or treatment. We should look to society, not to the brain.
Source: bostonreview.net
Clerkenwell Health raises £2.1m to test the new wave of psychedelics treatments
Clerkenwell Health a psychedelic-specialist clinical research organisation, has raised £2.1m in seed funding, bringing the total to date up to £2.5m, which will be used to get the London startup-based fully operational.
Source: techcrunch.com